Abstracts Archive - Page 2035 of 2425 - ACR Meeting Abstracts

Abstract Number: 253 • 2014 ACR/ARHP Annual Meeting
Evaluating Neuropathic Complaints By DN4 and Lanss Scales after Local Corticosteroid Therapy in Carpal Tunnel Syndrome
Taner Dandinoglu¹, Murat Karadeniz², Volkan Yılmaz³, Levent Tekin⁴ and Ümit Dinçer⁴, ¹Physical Medicine and Rehabilitation, Bursa Military Hospital, Bursa, Turkey, ²Physical Medicine and Rehabilitation, Çorlu Military Hospital, Tekirdağ, Turkey, ³Physical Medicine and Rehabilitation, Mevki Military Hospital, Ankara, Turkey, ⁴Physical Medicine and Rehabilitation, Gülhane Military Medical Academy, Haydarpaşa Training Hospital, İstanbul, Turkey

Background/Purpose: The purpose of this study was to evaluate the neuropathic symptoms after local steroid injection in CTS. Since 2001, neuropathic pain scales have…
Abstract Number: 251 • 2014 ACR/ARHP Annual Meeting
Chronic Fatigue Is Associated with Hypoperfusion of Parahippocampal Gyrus
Andrew O'Shea¹, Jason Craggs¹, Ricky Madhavan², Donald Price³, Song Lai⁴, Michael Robinson¹ and Roland Staud⁵, ¹Clinical & Health Psychology, University of Florida, Gainesville, FL, ²Medicine/Rheumatology, University of Florida, Gainesville, FL, ³Maxillo-Facial Surgery, University of Florida, Gainesville, FL, ⁴Radiation Oncology, University of Florida, Gainesville, FL, ⁵Dept Med/Rheum/Clin Immun Div, Univ of Florida Med Ctr/JHMHC, Gainesville, FL
Background/Purpose: Cerebral hypoperfusion of the whole brain has previously been reported in chronic fatigue syndrome (CFS) patients. However, discrepancies exist in the literature in regards…
Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting
Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Paul M. Peloso¹, Ted R. Mikuls², Brian W. Coburn³, H. Ralph Schumacher Jr.⁴, Davis F. Gates¹, Zoran Popmihajlov¹, Walter L. Straus¹ and R. Andrew Moore⁵, ¹Merck & Co., Inc., Whitehouse Station, NJ, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Oxford, Nuffield Division of Anaesthetics, Oxford, England
Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…
Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting
A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes
Vibeke Strand¹, Allan Gibofsky², Marc Hochberg³, Roy Altman⁴, Byron Cryer⁵, Alan Kivitz⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹Stanford University, Palo Alto, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³University of Maryland School of Medicine, College Park, MD, ⁴University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting
Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Proton Rahman¹, Algis Jovaisas², William Bensen³, Wojciech Olszynski⁴, Anna Jaroszynska⁵, Philip Baer⁶, Maqbool Sheriff⁷, Dalton Sholter⁸, Eliofotisti Psaradellis⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and May Shawi¹⁰, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Burlington, ON, Canada, ⁶Private Practice, Scarborough, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…
Abstract Number: 247 • 2014 ACR/ARHP Annual Meeting
Cognitive Task Related Hypoperfusion of Frontal Gyrus in Patients with Chronic Fatigue
Jason Craggs¹, Song Lai², Ricky Madhavan³, Donald Price⁴, Michael Robinson¹ and Roland Staud⁵, ¹Clinical & Health Psychology, University of Florida, Gainesville, FL, ²Radiation Oncology, University of Florida, Gainesville, FL, ³Medicine/Rheumatology, University of Florida, Gainesville, FL, ⁴Maxillo-Facial Surgery, University of Florida, Gainesville, FL, ⁵Dept Med/Rheum/Clin Immun Div, Univ of Florida Med Ctr/JHMHC, Gainesville, FL
Background/Purpose: Patient with Chronic Fatigue Syndrome (CFS) frequently report cognitive complaints, including lack of concentration and forgetfulness. Previous neuropsychological studies reported attentional and memory dysfunction…
Abstract Number: 246 • 2014 ACR/ARHP Annual Meeting
Neuropathic PAIN in Patients with Ankylosing Spondylitis
Pinar Borman¹, Ferda Kaygisiz², Aysegul Yaman¹ and Aynur Karagoz², ¹Department of Physical Medicine and Rehabilitation, University of Hacettepe Faculty of Medicine, Ankara, Turkey, ²Clinic of Physical Medicine and Rehabilitation, Ankara Training and Research Hospital, Ankara, Turkey
Background/Purpose: There is only one study in the literature indicating that neuropathic pain occurs in ankylosing spondylitis (AS) (1). Methods: The aim of this cross…
Abstract Number: 244 • 2014 ACR/ARHP Annual Meeting
Onset, Magnitude, and Durability of Pain Relief in Patients with Knee OA Receiving a Fixed-Dose Combination Tablet of Enteric-Coated (EC) Naproxen Plus Immediate-Release (IR) Esomeprazole Magnesium Versus Celecoxib and Placebo: Pooled Results from Two Randomized Controlled Trials
John Fort¹, Robert Holt², Amy Y. Grahn³, Jana Steinmetz⁴, Ying Zhang⁵ and Jeffery Kent⁶, ¹Pozen, Inc, Chapel Hill, NC, ²College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ³Horizon Pharma, Inc., Deerfield, IL, ⁴Statistics, Premier Research, Naperville, IL, ⁵Biostatistics, Pozen, Inc, Chapel Hill, NC, ⁶Medical Affairs, Horizon Pharma, Inc, Deerfield, IL
Background/Purpose: Over 40% of patients with OA report having significant knee pain every day. (1) Previously published data have demonstrated the overall comparable efficacy of…
Abstract Number: 243 • 2014 ACR/ARHP Annual Meeting
Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study
Roy Altman¹, Allan Gibofsky², Marc C. Hochberg³, Byron Cryer⁴, Alan J. Kivitz⁵, Vibeke Strand⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology & Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Stanford University, Palo Alto, CA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Osteoarthritis (OA) is a frequent cause of disability in adults. NSAIDs such as diclofenac are often prescribed to treat OA pain. However, NSAIDs…
Abstract Number: 242 • 2014 ACR/ARHP Annual Meeting
WOMAC Pain Score Reflects Preceding Daily Pain Ratings in Knee Osteoarthritis Interventional Randomized Clinical Trials
Michael H. V. Nguyen¹, Renita Evonne Yeasted² and Thomas J. Schnitzer³, ¹University of Washington School of Medicine, Seattle, WA, ²PM&R, Northwestern University, Chicago, IL, ³PM&R and Int Med, Northwestern University, Chicago, IL
Background/Purpose The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a validated and widely used instrument for assessing osteoarthritis (OA) knee and hip pain,…
Abstract Number: 241 • 2014 ACR/ARHP Annual Meeting
Reduced Estimated Glomerular Filtration Rate Was Improved after Cessation of NSAID and Switching to Tramadol Hydrochloride/Acetaminophen Tablets (Ultracet^TM) in Patients with Chronic Musculoskeletal Pain
Kenji Miki^1,2,3,4, Hiroshi Kajiyama⁵, Kenrin Shi^2,6,7, Shigeshi Mori¹, Masao Yukioka⁸ and Masao Akagi¹, ¹Department of Orthopaedic Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan, ²Center for Pain Management, Osaka University Hospital, Suita, Japan, ³Dept. of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁴Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁵Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ⁶Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁸Department of Rheumatology, Yukioka Hospital, Osaka, Japan
Background/Purpose: NSAID is widely used in patients with chronic musculoskeletal pain, but often deteriorates renal function with acute decline of estimated glomerular filtration rate (eGFR).…
Abstract Number: 240 • 2014 ACR/ARHP Annual Meeting
An Observational Study on the Influence of Glucocorticoid Exposure on Bone
Joseph Heath¹, Alexander Oldroyd², Maarten Boers³ and Marwan Bukhari², ¹Faculty of health and medicine, Lancaster University, Lancaster, United Kingdom, ²Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ³Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose It is well known that glucocorticoids are detrimental to bone health and has been postulated that their influence is more than their effect on…
Abstract Number: 239 • 2014 ACR/ARHP Annual Meeting
Does Adjusting BMI for Lean Mass Deficits Affect Calculated Fracture Risk Using FRAX in Rheumatoid Arthritis?
Brittany Adler¹ and Joshua F. Baker², ¹Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA
Background/Purpose Osteoporotic fractures are a cause of morbidity in rheumatoid arthritis (RA) and low body mass index (BMI) is a risk factor for osteoporotic fractures…
Abstract Number: 236 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Prevalent and Progressive Bone Deficits Among Adult Men and Women with Cystic Fibrosis
Joshua Baker¹, Putman Melissa², Karen Herlyn³, Angela S. Pizzo⁴, Allen Lapey⁵, Joel Finklestein² and Peter A. Merkel⁶, ¹Medicine/Rheumatology, Philadelphia VA Medical Center, Philadelphia, PA, ²Harvard University, Boston, MA, ³Department of Rheumatology, University Hospital Schleswig-Holstein, Lübeck, Germany, ⁴Mercy Hospital, Portland, ME, ⁵Cystic Fibrosis Center and Division of Pediatric Pulmonology, Massachusetts General Hospital, Boston, MA, ⁶University of Pennsylvania, Philadelphia, PA
Risk Factors for Prevalent and Progressive Bone Deficits Among Adult Men and Women with Cystic FibrosisBackground/Purpose Cystic Fibrosis (CF) is associated with an increased risk…
Abstract Number: 235 • 2014 ACR/ARHP Annual Meeting
Lower P1NP Serum Levels: a Predictive Marker of Bone Loss after One-Year Follow-up in premenopausal SLE Patients
Luciana Seguro¹, Caio B. Casella¹, Valéria Caparbo¹, Ricardo M. Oliveira², Alessandra C Bonfa¹, Eloisa Bonfa¹ and Rosa M R Pereira¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²RDO Diagnosticos Medicos, São Paulo, Brazil
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with high risk of low bone mass/fractures but this risk is still controversial in premenopausal women. Our aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].